Facilitation of suction termination using extra-amniotic prostaglandins in gel.
Extra-amniotic prostaglandin E2 (PGE2) suspended in a slow release gel (Tylose) was instilled in 35 patients prior to a planned surgical termination in an attempt to dilate the cervix, minimize cervical trauma, and reduce the possible risk of cervical trauma, and reduce the possible risk of cervical incompetence and its sequelae. Dilatation occurred in all patients to a minimum of 8 mm and 74% aborted before surgical evacuation performed 6 to 24 hours after injection. No serious side effects occurred. Extra-amniotic PGE2 in gel should be considered as a primary procedure when the cervix is obviously immature on examination. If the cervix is found to be tight and unyielding at surgical dilatation, the latter procedure should be dicontinued and PGE2 in gel injected.
D000028:Abortion, Induced; D002584:Cervix Uteri / Q000187:drug effects*; D004107:Dilatation and Curettage; D004305:Dose-Response Relationship, Drug; D005260:Female; D005782:Gels; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011292:Premedication; D011458:Prostaglandins E / Q000008:administration & dosage; D014619:Vacuum Curettage
D005782:Gels; D011458:Prostaglandins E